215 related articles for article (PubMed ID: 20889917)
41. Therapeutic potential of GSK-J4, a histone demethylase KDM6B/JMJD3 inhibitor, for acute myeloid leukemia.
Li Y; Zhang M; Sheng M; Zhang P; Chen Z; Xing W; Bai J; Cheng T; Yang FC; Zhou Y
J Cancer Res Clin Oncol; 2018 Jun; 144(6):1065-1077. PubMed ID: 29594337
[TBL] [Abstract][Full Text] [Related]
42. Evaluation of artemisinins for the treatment of acute myeloid leukemia.
Drenberg CD; Buaboonnam J; Orwick SJ; Hu S; Li L; Fan Y; Shelat AA; Guy RK; Rubnitz J; Baker SD
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1231-43. PubMed ID: 27125973
[TBL] [Abstract][Full Text] [Related]
43. Valproic acid triggers differentiation and apoptosis in AML1/ETO-positive leukemic cells specifically.
Zapotocky M; Mejstrikova E; Smetana K; Stary J; Trka J; Starkova J
Cancer Lett; 2012 Jun; 319(2):144-153. PubMed ID: 22261333
[TBL] [Abstract][Full Text] [Related]
44. Valproic acid combined with cytosine arabinoside in elderly patients with acute myeloid leukemia has in vitro but limited clinical activity.
Lane S; Gill D; McMillan NA; Saunders N; Murphy R; Spurr T; Keane C; Fan HM; Mollee P
Leuk Lymphoma; 2012 Jun; 53(6):1077-83. PubMed ID: 22098405
[TBL] [Abstract][Full Text] [Related]
45. Effects of cytarabine on activation of human T cells - cytarabine has concentration-dependent effects that are modulated both by valproic acid and all-trans retinoic acid.
Ersvaer E; Brenner AK; Vetås K; Reikvam H; Bruserud Ø
BMC Pharmacol Toxicol; 2015 May; 16():12. PubMed ID: 25934555
[TBL] [Abstract][Full Text] [Related]
46. Chidamide in FLT3-ITD positive acute myeloid leukemia and the synergistic effect in combination with cytarabine.
Li X; Yan X; Guo W; Huang X; Huang J; Yu M; Ma Z; Xu Y; Huang S; Li C; Zhou Y; Jin J
Biomed Pharmacother; 2017 Jun; 90():699-704. PubMed ID: 28419965
[TBL] [Abstract][Full Text] [Related]
47. Histone deacetylases 1 and 2 cooperate in regulating BRCA1, CHK1, and RAD51 expression in acute myeloid leukemia cells.
Zhao J; Xie C; Edwards H; Wang G; Taub JW; Ge Y
Oncotarget; 2017 Jan; 8(4):6319-6329. PubMed ID: 28030834
[TBL] [Abstract][Full Text] [Related]
48. Downregulation of c-Myc is critical for valproic acid-induced growth arrest and myeloid differentiation of acute myeloid leukemia.
Cheng YC; Lin H; Huang MJ; Chow JM; Lin S; Liu HE
Leuk Res; 2007 Oct; 31(10):1403-11. PubMed ID: 17445886
[TBL] [Abstract][Full Text] [Related]
49. The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR.
Zhou L; Chen S; Zhang Y; Kmieciak M; Leng Y; Li L; Lin H; Rizzo KA; Dumur CI; Ferreira-Gonzalez A; Rahmani M; Povirk L; Chalasani S; Berger AJ; Dai Y; Grant S
Blood; 2016 May; 127(18):2219-30. PubMed ID: 26851293
[TBL] [Abstract][Full Text] [Related]
50. Integrated genomic analyses identify WEE1 as a critical mediator of cell fate and a novel therapeutic target in acute myeloid leukemia.
Porter CC; Kim J; Fosmire S; Gearheart CM; van Linden A; Baturin D; Zaberezhnyy V; Patel PR; Gao D; Tan AC; DeGregori J
Leukemia; 2012 Jun; 26(6):1266-76. PubMed ID: 22289989
[TBL] [Abstract][Full Text] [Related]
51. FLT3-ITD-, but not BCR/ABL-transformed cells require concurrent Akt/mTor blockage to undergo apoptosis after histone deacetylase inhibitor treatment.
Cai D; Wang Y; Ottmann OG; Barth PJ; Neubauer A; Burchert A
Blood; 2006 Mar; 107(5):2094-7. PubMed ID: 16304046
[TBL] [Abstract][Full Text] [Related]
52. The topoisomerase II inhibitor voreloxin causes cell cycle arrest and apoptosis in myeloid leukemia cells and acts in synergy with cytarabine.
Walsby EJ; Coles SJ; Knapper S; Burnett AK
Haematologica; 2011 Mar; 96(3):393-9. PubMed ID: 21134979
[TBL] [Abstract][Full Text] [Related]
53. Hematologic improvement and response in elderly AML/RAEB patients treated with valproic acid and low-dose Ara-C.
Corsetti MT; Salvi F; Perticone S; Baraldi A; De Paoli L; Gatto S; Pietrasanta D; Pini M; Primon V; Zallio F; Tonso A; Alvaro MG; Ciravegna G; Levis A
Leuk Res; 2011 Aug; 35(8):991-7. PubMed ID: 21474179
[TBL] [Abstract][Full Text] [Related]
54. Synergistic activity and mechanism of cytarabine and MCL-1 inhibitor AZD5991 against acute myeloid leukemia.
Wang Y; Wang D; Wang Y; Yang H; Wang G; Wu S
Neoplasma; 2023 Apr; 70(2):287-293. PubMed ID: 36812234
[TBL] [Abstract][Full Text] [Related]
55. Surmounting Cytarabine-resistance in acute myeloblastic leukemia cells and specimens with a synergistic combination of hydroxyurea and azidothymidine.
Levin M; Stark M; Berman B; Assaraf YG
Cell Death Dis; 2019 May; 10(6):390. PubMed ID: 31101804
[TBL] [Abstract][Full Text] [Related]
56. Effects of valproic acid on the cell cycle and apoptosis through acetylation of histone and tubulin in a scirrhous gastric cancer cell line.
Yagi Y; Fushida S; Harada S; Kinoshita J; Makino I; Oyama K; Tajima H; Fujita H; Takamura H; Ninomiya I; Fujimura T; Ohta T; Yashiro M; Hirakawa K
J Exp Clin Cancer Res; 2010 Nov; 29(1):149. PubMed ID: 21080974
[TBL] [Abstract][Full Text] [Related]
57. Emodin and Its Combination with Cytarabine Induce Apoptosis in Resistant Acute Myeloid Leukemia Cells in Vitro and in Vivo.
Chen Y; Gan D; Huang Q; Luo X; Lin D; Hu J
Cell Physiol Biochem; 2018; 48(5):2061-2073. PubMed ID: 30099447
[TBL] [Abstract][Full Text] [Related]
58. The cyclin-dependent kinase inhibitor SNS-032 has single agent activity in AML cells and is highly synergistic with cytarabine.
Walsby E; Lazenby M; Pepper C; Burnett AK
Leukemia; 2011 Mar; 25(3):411-9. PubMed ID: 21212792
[TBL] [Abstract][Full Text] [Related]
59. Cooperative effect of chidamide and chemotherapeutic drugs induce apoptosis by DNA damage accumulation and repair defects in acute myeloid leukemia stem and progenitor cells.
Li Y; Wang Y; Zhou Y; Li J; Chen K; Zhang L; Deng M; Deng S; Li P; Xu B
Clin Epigenetics; 2017; 9():83. PubMed ID: 28814980
[TBL] [Abstract][Full Text] [Related]
60. Systemic Metabolomic Profiling of Acute Myeloid Leukemia Patients before and During Disease-Stabilizing Treatment Based on All-Trans Retinoic Acid, Valproic Acid, and Low-Dose Chemotherapy.
Grønningsæter IS; Fredly HK; Gjertsen BT; Hatfield KJ; Bruserud Ø
Cells; 2019 Oct; 8(10):. PubMed ID: 31658693
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
